The FDA approved Sanofi and Regeneron Pharmaceuticals drug Dupixent as a treatment for the inflammatory skin disorder chronic spontaneous urticaria. The regulatory decision comes two years after the agency turned down an application for the biologic drug in this indication.
The post Blockbuster Sanofi & Regeneron Drug Dupixent Notches FDA Nod for an Inflammatory Skin Disease appeared first on MedCity News.
